[go: up one dir, main page]

FI940144L - Vasta-aineiden tuotanto - Google Patents

Vasta-aineiden tuotanto Download PDF

Info

Publication number
FI940144L
FI940144L FI940144A FI940144A FI940144L FI 940144 L FI940144 L FI 940144L FI 940144 A FI940144 A FI 940144A FI 940144 A FI940144 A FI 940144A FI 940144 L FI940144 L FI 940144L
Authority
FI
Finland
Prior art keywords
antibody production
antibody
production
Prior art date
Application number
FI940144A
Other languages
English (en)
Swedish (sv)
Other versions
FI940144A0 (fi
FI940144A7 (fi
Inventor
James Scott Crowe
Alan Peter Lewis
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27265765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI940144(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919115284A external-priority patent/GB9115284D0/en
Priority claimed from GB919116594A external-priority patent/GB9116594D0/en
Priority claimed from GB929206284A external-priority patent/GB9206284D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of FI940144A0 publication Critical patent/FI940144A0/fi
Publication of FI940144A7 publication Critical patent/FI940144A7/fi
Publication of FI940144L publication Critical patent/FI940144L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/106—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI940144A 1991-07-15 1992-07-14 Vasta-aineiden tuotanto FI940144L (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB919115284A GB9115284D0 (en) 1991-07-15 1991-07-15 Production of antibodies
GB919116594A GB9116594D0 (en) 1991-08-01 1991-08-01 Production of antibodies
GB929206284A GB9206284D0 (en) 1992-03-23 1992-03-23 Production of antibodies
PCT/GB1992/001282 WO1993002190A1 (en) 1991-07-15 1992-07-14 Production of antibodies

Publications (3)

Publication Number Publication Date
FI940144A0 FI940144A0 (fi) 1994-01-12
FI940144A7 FI940144A7 (fi) 1994-01-12
FI940144L true FI940144L (fi) 1994-01-12

Family

ID=27265765

Family Applications (1)

Application Number Title Priority Date Filing Date
FI940144A FI940144L (fi) 1991-07-15 1992-07-14 Vasta-aineiden tuotanto

Country Status (16)

Country Link
US (1) US5876961A (fi)
EP (1) EP0523949B1 (fi)
JP (1) JP3502093B2 (fi)
KR (1) KR100255717B1 (fi)
AT (1) ATE243747T1 (fi)
AU (1) AU662752B2 (fi)
CA (1) CA2111858A1 (fi)
DE (1) DE69233104T2 (fi)
ES (1) ES2199216T3 (fi)
FI (1) FI940144L (fi)
HU (1) HU220355B (fi)
IE (1) IE922287A1 (fi)
IL (1) IL102490A0 (fi)
NZ (1) NZ243558A (fi)
TW (1) TW373023B (fi)
WO (1) WO1993002190A1 (fi)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
NZ243706A (en) * 1991-07-25 1994-08-26 Idec Pharma Corp Recombinant monkey antibodies, pharmaceutical compositions
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
US20020122807A1 (en) * 1998-07-07 2002-09-05 Dan Michael D. Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US20030180284A1 (en) * 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
WO2001066754A1 (en) 2000-03-03 2001-09-13 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
EP1589034B1 (en) * 2000-12-05 2008-11-19 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
CA2872136C (en) 2002-07-18 2017-06-20 Merus B.V. Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
AU2004242614B2 (en) 2003-05-30 2011-09-22 Merus N.V. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ES2646560T3 (es) 2004-01-20 2017-12-14 Merus N.V. Mezclas de proteínas de unión
BRPI0513135A (pt) 2004-07-06 2008-04-29 Bioren Inc bibliotecas de polinucleotìdeos, método de produção das mesmas, método de identificação de um polinucleotìdeo, região de ligação, meio adequado para uso em um, dispositivo eletrÈnico e dispositivo
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
ITRM20050297A1 (it) * 2005-06-08 2006-12-09 Univ Siena Anticorpi diretti contro la proteina basica della mielina che riconoscono un epitopo del cd64 e uso di essi come immunodepressivi.
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TWI548747B (zh) 2006-09-13 2016-09-11 艾伯維有限公司 細胞培養改良
US8680235B2 (en) 2006-09-22 2014-03-25 Stowers Institute For Medical Research Branchiostoma derived fluorescent proteins
EP2098536A1 (en) 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
EP2356227B1 (en) 2008-11-14 2018-03-28 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
US9079942B2 (en) 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
US20100317539A1 (en) * 2009-06-12 2010-12-16 Guo-Liang Yu Library of Engineered-Antibody Producing Cells
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
US10288611B2 (en) 2009-11-23 2019-05-14 The Johns Hopkins University Lateral flow device for diagnosing microbial infections
US10585098B2 (en) 2009-11-23 2020-03-10 The Johns Hopkins University Optimizing diagnostics for galactofuranose containing antigens
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
CN114163530B (zh) 2012-04-20 2025-04-29 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
BR112015000167B1 (pt) 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2890782A1 (en) 2012-09-02 2015-07-08 AbbVie Inc. Methods to control protein heterogeneity
SG10201705787VA (en) 2012-09-27 2017-08-30 Merus Nv BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
JP6205175B2 (ja) 2013-05-16 2017-10-04 株式会社Ｒｅｓｖｏ 精神・神経疾患バイオマーカー
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015095195A1 (en) 2013-12-16 2015-06-25 The Johns Hopkins University Interferon-gamma release assays for diagnosis of invasive fungal infections
SG11201607104RA (en) 2014-02-28 2016-09-29 Merus Nv Antibody that binds erbb-2 and erbb-3
ES2816624T3 (es) 2014-02-28 2021-04-05 Merus Nv Anticuerpos que se unen a EGFR y ERBB3
EA201890028A1 (ru) 2015-07-10 2018-08-31 Мерус Н.В. Антитело, связывающее cd3 человека
HRP20210483T1 (hr) 2015-10-23 2021-07-09 Merus N.V. Vezujuće molekule koje inhibiraju rast raka
KR20260006707A (ko) 2017-03-31 2026-01-13 메뤼스 엔.페. NRG1 융합 유전자를 가지는 세포를 치료하기 위한 ErbB2 및 ErbB3 결합 이중특이적 항체
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
AU2018271157C1 (en) 2017-05-17 2021-11-18 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
DK3665198T3 (da) 2017-08-09 2025-04-28 Merus Nv Antistoffer, der binder egfr og cmet
TW201930351A (zh) 2017-10-06 2019-08-01 日商小野藥品工業股份有限公司 雙特異性抗體
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
TWI862565B (zh) 2019-04-04 2024-11-21 日商小野藥品工業股份有限公司 雙特異性抗體
TWI809286B (zh) 2019-07-05 2023-07-21 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
CN114174343A (zh) 2019-07-30 2022-03-11 小野药品工业株式会社 双特异性抗体
EP4011918A4 (en) 2019-08-08 2023-08-23 ONO Pharmaceutical Co., Ltd. DUAL SPECIFIC PROTEIN
IL318949A (en) 2022-08-23 2025-04-01 Ono Pharmaceutical Co Bispecific antibody

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296024A (en) * 1974-12-09 1981-10-20 Merck & Co., Inc. Human immune serum globulin with high hepatitis A antibody titer
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
CH652145A5 (de) * 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
EP0131878A3 (en) * 1983-07-19 1987-08-05 Sloan-Kettering Institute For Cancer Research Process for producing human monoclonal antibodies
US4777245A (en) * 1984-01-06 1988-10-11 Genelabs Incorporated Non-human primate monoclonal antibodies and methods
US4997764A (en) * 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
AU2083688A (en) * 1987-07-09 1989-02-13 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Preparation of human monoclonal antibodies of selected specificity and isotypes
NZ226694A (en) * 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
KR0161525B1 (ko) * 1988-10-19 1998-12-01 리챠드 지. 워터맨 암치료를 위한 신규의 고친화성 변형된 항체군
DE3921211C1 (fi) * 1989-06-28 1990-11-29 Idt Ag Fuer In Vivo Diagnostik Und Therapie, Zuerich, Ch
WO1991004336A1 (en) * 1989-09-19 1991-04-04 Centocor, Inc. Method for improving human monoclonal antibody production
GB8925590D0 (en) 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
DE4002897A1 (de) * 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
ES2225816T5 (es) * 1990-02-01 2014-08-21 Siemens Healthcare Diagnostics Products Gmbh Producción y utilización de bancos de genes de anticuerpos humanos ("bibliotecas de anticuerpos humanos")
NZ243706A (en) * 1991-07-25 1994-08-26 Idec Pharma Corp Recombinant monkey antibodies, pharmaceutical compositions

Also Published As

Publication number Publication date
NZ243558A (en) 1994-06-27
EP0523949A1 (en) 1993-01-20
FI940144A0 (fi) 1994-01-12
US5876961A (en) 1999-03-02
IE922287A1 (en) 1993-01-27
EP0523949B1 (en) 2003-06-25
TW373023B (en) 1999-11-01
FI940144A7 (fi) 1994-01-12
CA2111858A1 (en) 1993-02-04
JPH07502882A (ja) 1995-03-30
DE69233104D1 (de) 2003-07-31
HUT69798A (en) 1995-09-28
ATE243747T1 (de) 2003-07-15
DE69233104T2 (de) 2004-05-13
HU9400110D0 (en) 1994-05-30
HU220355B (hu) 2001-12-28
AU2279892A (en) 1993-02-23
WO1993002190A1 (en) 1993-02-04
ES2199216T3 (es) 2004-02-16
JP3502093B2 (ja) 2004-03-02
IL102490A0 (en) 1993-01-14
KR100255717B1 (ko) 2000-05-01
AU662752B2 (en) 1995-09-14

Similar Documents

Publication Publication Date Title
FI940144A7 (fi) Vasta-aineiden tuotanto
FI930580L (fi) Tri- och tetravalensiska monopecifika antigen bindande proteiner
FI941135L (fi) Uusi biomenetelmä 7-ADCA:n valmistamiseksi
ATE137279T1 (de) Stoffauflauf
FI942835A7 (fi) Proteiinin valmistus
ATA131391A (de) Reibring
FI910116L (fi) sigma-delta-modulator foer d/a-omvandlare
FI923342L (fi) Pleuromutilinkomplex
DE69219741D1 (de) Hydrolisylierungsverfahren
FI922681L (fi) Nytt foerpacknings/behaollarsystem
GB9114468D0 (en) Antibody production
DK0512652T3 (da) Hydrodecykliseringsfremgangsmåde
FI934447A0 (fi) Nytt immunhaemmande aemne fraon strptomyces braegensis
FI922683L (fi) Nytt foerpacknings/behaollarsystem
ATA39792A (de) Maehwerk
ATA170491A (de) Mauerstein
DK474189D0 (da) Antistof
ATE163916T1 (de) Ethyl-6-formyloxy-4-hexenoat
FI922682L (fi) Nytt foerpacknings/behaollarsystem
ATA67791A (de) Rollski
ATA9892A (de) Formstein
ITMI913363A0 (it) Produzione di tattolio
GB9105532D0 (en) Antibody production
FI924046L (fi) Pan-strukturformstycke
DK0540107T3 (da) Klinkerproduktionsanlæg